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Abstract
Background: Hypophosphataemia after a hepatectomy suggests hepatic regeneration. It was hypoth-
esized that the absence of hypophosphataemia is associated with post-operative hepatic insufficiency
(PHI) and complications.
Methods: Patients who underwent a major hepatectomy from 2000–2012 at a single institution were
identified. Post-operative serum phosphorus levels were assessed. Primary outcomes were PHI (peak
bilirubin >7 mg/dl), major complications, and 30- and 90-day mortality.
Results: Seven hundred and nineteen out of 749 patients had post-operative phosphorus levels
available. PHI and major complications occurred in 63 (8.8%) and 169 (23.5%) patients, respectively.
Thirty- and 90-day mortality were 4.0% and 5.4%, respectively. The median phosphorus level on
post-operative-day (POD) 2 was 2.2 mg/dl; 231 patients (32.1%) had phosphorus >2.4 on POD2.Patients
with POD2 phosphorus >2.4 had a significantly higher incidence of PHI, major complications and
mortality. On multivariate analysis, POD2 phosphorus >2.4 remained a significant risk factor for PHI
[(hazard ratio HR):1.78; 95% confidence interval (CI):1.02–3.17; P = 0.048], major complications (HR:1.57;
95%CI:1.02–2.47; P = 0.049), 30-day mortality (HR:2.70; 95%CI:1.08–6.76; P = 0.034) and 90-day
mortality (HR:2.51; 95%CI:1.03–6.15; P = 0.044). Similarly, patients whose phosphorus level reached
nadir after POD3 had higher PHI, major complications and mortality.
Conclusion: Elevated POD2 phosphorus levels >2.4 mg/dl and a delayed nadir in phosphorus beyond
POD3 are associated with increased post-operative hepatic insufficiency, major complications and early
mortality. Failure to develop hypophosphataemia within 72 h after a major hepatectomy may reflect
insufficient liver remnant regeneration.
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Introduction
Hypophosphataemia is a commonly observed phenomenon after
a major hepatic resection. While small prior case series describing
this occurrence have focused on the risk of complications associ-
ated with profound hypophosphataemia after a hepatectomy,1–4 a
decrease in the circulating level of serum phosphorus is an
expected and appropriate physiological sequela of a liver
resection.5–7 Serum phosphorus levels after a major hepatic resec-
tion follow a characteristic trend, typically decreasing over the first
72 h to reach a nadir by postoperative day (POD) 2 or 3, before
slowly increasing back to pre-operative levels by POD 5–7.1–3,5
While the regulatory mechanisms for this phenomenon are
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likely multi-factorial, hypophosphataemia after a hepatectomy is
thought to partially reflect physiological regeneration of the
remaining liver remnant.
The unique regenerative potential of hepatocytes and the
compensatory capacity of the functional liver remnant post-
hepatectomy allow for the resection of up to 75–80% of a non-
diseased liver.8,9 Liver regeneration commences early and reaches
its kinetic maximum over the first 72 h after a hepatectomy; the
process is remarkably efficient, with functional compensation for
the liver’s synthetic and enzymatic demands often complete by
POD 5–7.10,11 The liver demonstrates significant early uptake of
serum phosphorus, which peaks during the first few days post-
hepatectomy, corresponding to the period of maximum liver
regeneration and correlating with the decrease in free serum phos-
phorus levels commonly observed.12,13 The maximum metabolic
demand on the regenerating liver typically occurs during the first
72 h, with the decrease in serum phosphorus levels post-
hepatectomy mirroring this pattern.11,14–18
Patients who develop post-operative hepatic insufficiency
(PHI) after a hepatectomy do not exhibit the same appropriate
regenerative response, and may demonstrate insufficient func-
tional compensation as early as POD 1 or 2 compared with those
with appropriate liver remnant regeneration.10 As a result of inad-
equate or delayed hepatic regeneration, patients at risk for PHI
may exhibit early derangements in normal metabolic responses,
such as a failure to appropriately utilize phosphorus. Thus, early
signs of inadequate liver regeneration may include failure to
develop hypophosphataemia or a delayed decrease in serum phos-
phorus levels that normally occurs during the first 72 h.
It was hypothesized that after a major hepatectomy, absence of
expected post-operative hypophosphataemia or delayed develop-
ment of hypophosphataemia may be associated with poor liver
remnant regeneration and an increased risk of PHI, complications
and early mortality.
Patients and methods
This study protocol was conducted with the approval of the Insti-
tution Review Board and in accordance with the Health Insurance
Portability and Accountability Act of 1996. From a prospectively
maintained institutional database, all patients who underwent a
major hepatectomy, defined as resection of three or more hepatic
segments, between January 2000 and July 2012 were identified.
From a thorough retrospective chart review of all patients’
medical records, pre-operative demographics and peri-operative
clinicopathological variables were collected. All available post-
operative serum phosphorus levels were collected from the first
seven post-operative days; the day on which each patient’s post-
operative phosphorus nadir (i.e. the lowest absolute level rec-
orded) was reached during these first 7 days was also determined.
The institutional laboratory reference range for normal serum
phosphorus levels is 2.4–4.7 mg/dl. Failure to develop or delayed
development of post-hepatectomy hypophosphataemia was
evaluated on the basis of two distinct variables: the absolute serum
phosphorus level, as well as the post-operative day on which
patients reached their nadir phosphorus value. As most patients
with appropriate liver regeneration were predicted to develop
some degree of hypophosphataemia by POD2, POD2 phosphorus
level was analysed as a dichotomous variable, with 2.4 mg/dl, the
lower limit of normal reference range, selected as the cutoff. Simi-
larly, patients with appropriate liver regeneration were predicted
to reach their nadir phosphorus level within the first 72 h; thus
patients were dichotomized into those who reached their phos-
phorus nadir during POD1 through POD3 compared with those
who demonstrated a delayed phosphorus nadir after POD3.
Serum phosphorus levels on POD2 were also analysed accord-
ing to the definitions proposed by George and Shiu:2 normal
phosphorus (>2.5 mg/dl), moderate hypophosphataemia (1.6–
2.5 mg/dl), severe hypophosphataemia (1.1–1.5 mg/dl), or pro-
found hypophosphataemia (<1.1 mg/dl).
The total amount of post-operative phosphorus repletion over
the first 72 h post-hepatectomy, accounting for both maintenance
intravenous (i.v.) fluids as well as any bolus i.v. or oral repletion
doses, was quantified (in millimoles) based on a thorough review
of the medical administration record. Phosphorus repletion was
at the discretion of the attending surgeon and did not follow a
standardized protocol or regimen.
Primary outcomes assessed were post-operative hepatic insuf-
ficiency, defined as a peak post-operative serum bilirubin
>7.0 mg/dl as first described by Mullen et al.19 major complica-
tions, defined as Grade III-V complications according to the
Clavien–Dindo classification system,20 and 30-day and 90-day
mortality.
Univariate and multivariate (MV) logistic regression analysis
were used to evaluate the association of all pertinent pre- and
peri-operative variables with each endpoint. All variables with a
P-value ≤0.05 on univariate analysis were included into the mul-
tivariate model. Separate distinct MV models were developed to
independently assess the association of each endpoint with POD2
phosphorus >2.4 mg/dl, as well as a delayed post-operative phos-
phorus nadir day beyond POD3. Statistical significance was
defined as a P-value <0.05. All statistical analyses were conducted
with SPSS 21.0 software (IBM, Inc., Armonk, NY, USA).
Results
Of the 749 patients who underwent a major hepatectomy from
2000–2012, 719 (96%) had post-operative serum phosphorus
levels available for analysis. Clinicopathological characteristics of
this cohort are summarized in Table 1.
The median serum phosphorus levels for the cohort are
depicted in Fig. 1a. The overall trajectory of a characteristic initial
steep decline and subsequent slow, incremental recovery was
similar for all patients undergoing a major hepatectomy, regard-
less of the extent of resection (Fig. 1b). The median phosphorus
level on POD2 was 2.2 mg/dl (interquartile range, 1.7–2.8) and
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231 patients (32.1%) had a POD2 phosphorus level that remained
>2.4 mg/dl, the lower limit of the normal reference range. In 589
(81.9%) patients, the phosphorus nadir occurred within the first 3
days post-hepatectomy; thus 130 patients (18.1%) had a delayed
post-operative phosphorus nadir after POD3.
Morbidity and mortality rates by degree of hypophosphataemia,
using the definitions proposed by George and Shiu,2 are shown in
Table 2; patients with ‘normal’ phosphorus levels (>2.5 mg/dl),
that is, those who failed to develop hypophosphataemia, had the
highest rates of PHI (12.3%),major complications (30.3%),30-day
mortality (6.5%) and 90-day mortality (7.1%) among the four
subgroups.
Using the institutional cutoff for hypophosphataemia of
2.4 mg/dl, on univariate analysis, patients with a POD2 phospho-
rus level >2.4 mg/dl demonstrated a significantly increased risk of
PHI [12.6% (29/231) vs. 6.9% (34/488); P = 0.020], major com-
plications [28.1% (65/231) vs. 21.3% (104/488); P = 0.031],
30-day mortality [7.8% (18/231) vs. 2.3% (11/488); P = 0.001] and
90-day mortality [8.7% (20/231) vs. 3.9% (19/488); P = 0.018].
Multivariate regression analyses of risk factors for PHI and
major complications are presented in Table 3a and for 30-day and
90-day mortality in Table 3b. On MV analysis, POD2 phosphorus
>2.4 mg/dl remained independently associated with a signifi-
cantly increased risk of PHI [hazard ratio (HR) 1.78; 95% confi-
dence interval (CI): 1.02–3.17; P = 0.048; Table 3a], major
complications (HR 1.57; 95% CI: 1.02–2.47; P = 0.049; Table 3a),
30-day mortality (HR 2.70; 95% CI: 1.08–6.76; P = 0.031;
Table 3b) and 90-day mortality (HR 2.51; 95% CI: 1.03–6.15;
P = 0.044; Table 3b).
Patients who experienced a delayed post-operative phosphorus
nadir beyond POD3 demonstrated a significantly increased risk of
PHI [13.1% (17/130) vs. 7.8% (46/589); P = 0.037], major com-
plications [37.6% (49/130) vs. 20.4% (120/589); P < 0.001],
30-day mortality [8.5% (11/130) vs. 3.1% (18/589); P = 0.009] and
90-day mortality [11.5% (15/130) vs. 4.1% (24/589); P = 0.004] on
univariate analysis.
On MV analysis assessing delayed phosphorus nadir as a
marker of inadequate liver regeneration, patients reaching their
phosphorus nadir after POD3 remained at a significantly
increased risk of PHI (HR 1.86; 95% CI: 1.02–3.39; P = 0.044;
Table 3c). Major complications (HR 1.90; 95% CI: 1.09–3.31; P =
0.022; Table 3c) and 30-day mortality (HR 2.39; 95% CI: 1.09–
5.72; P = 0.045; Table 3d) demonstrated a trend towards an
increased risk of 90-day mortality (HR 2.11; 95% CI: 0.99–4.49;
P = 0.054; Table 3d).
Four hundred ninety-six patients (69%) received phosphorus
repletion during the first 72 h post-operatively; the median
amount of repletion was 55 mmol (range, 10–170 mmol). Phos-
phorus repletion during the first 72 h post-hepatectomy was not
associated with a risk of PHI [8.5% (42/496) vs. 9.4% (21/223);
P = 0.802], major complications [22.4% (111/496) vs. 26.0% (58/
223); P = 0.544], or early mortality [3.6% (18/496) vs. 4.9% (11/
223); P = 0.408]. Neither the use of the Pringle manoeuver nor the
Table 1 Demographic and clinicopathological characteristics of
patients undergoing a major hepatectomy from 2000–2012 (n = 719)
Variable N (%) or median
[range]
Gender, male 298 (41%)
Race
White 467 (65%)
Black 164 (23%)
Other 88 (12%)
Age, median [range], years 57 [18–88]
BMI, median [range], kg/m2 26.4 [16.6–57.8]
ASA Class
2 229 (32%)
3 463 (64%)
4 20 (3%)
Hepatitis B 18 (3%)
Hepatitis C 20 (3%)
Smoking history, >10 pack-years 217 (30%)
Alcohol abuse 44 (6%)
Cancer diagnosis (indication for hepatectomy) 519 (72%)
Platelet count, median [range], × 103/ml 241 [69–900]
Albumin, median [range], gm/dl 3.6 [1.3–4.7]
Total bilirubin, median [range], mg/dl 0.6 [0.1–24.6]
INR, median [range] 1.00 [0.81–2.61]
Portal vein embolization 30 (4%)
Resection type
Extended left 41 (6%)
Extended right 143 (20%)
Left hemihepatectomy 163 (23%)
Right hemihepatectomy 279 (39%)
Central hepatectomy 17 (2%)
Non-anatomic 76 (10%)
Bile duct resection 143 (20%)
EBL, median [range], ml 400 [50–5900]
Intra-operative transfusion 184 (26%)
Pathology
Metastatic colorectal cancer 229 (32%)
Hepatocellular carcinoma 69 (9%)
Cholangiocarcinoma 88 (12%)
Metastatic NET 34 (5%)
Other 299 (42%)
Cirrhosis 26 (4%)
Steatosis 207 (29%)
Any complication 443 (61.6%)
Major complications (Grade III–V) 169 (23.5%)
Post-operative hepatic insufficiency (PHI) 63 (8.8%)
30-day mortality 29 (4.0%)
90-day mortality 39 (5.4%)
ASA, American Society of Anesthesiology; BMI, body mass index; EBL,
estimated blood loss; INR, international normalized ratio; NET,
neuroendocrine tumour.
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duration of vascular inflow occlusion when used was significantly
associated with the risk of PHI (P = 0.104), major complications
(P = 0.986), 30- (P = 0.945) or 90-day mortality (P = 0.763). The
use or duration of the Pringle manoeuver also did not correlate
with post-operative serum phosphorus, the degree of
hypophosphataemia, or the timing to reach phosphorus nadir
(data not shown).
Discussion
In this large series of patients who underwent a major hepatec-
tomy, failure to develop expected hypophosphataemia, whether
defined as a POD2 serum phosphorus level >2.4 mg/dl or as a
delayed nadir in serum phosphorus beyond POD3, was indepen-
dently associated with a significantly increased risk of PHI, major
complications and early mortality.
Previous series have been limited by small cohort sizes and the
inclusion of both minor and major hepatic resections. Several of
these small patient series over the past few decades examining
hypophosphataemia after a hepatectomy or live donor hepatec-
tomy have reported increased rates of post-operative complica-
tions.2,3,5,21 Other studies have failed to demonstrate an
association between hypophosphataemia and the risk of compli-
cations.1,6,7 Yet few of these studies have adequately acknowl-
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Figure 1 (a) Median serum phosphorus levels [with interquartile (25–75%) range] after a major hepatectomy. (b) Median serum phosphorus
levels [with interquartile (25–75%) range] stratified by the extent of major hepatectomy
Table 2 Relative frequency of post-operative hepatic insufficiency (PHI), major complications, 30- and 90-day mortality, stratified by
post-operative day 2 (POD2) phosphorus levels (as defined by George and Shiu2)
PHI Major
complications
30-day
mortality
90-day
mortality
‘Normal’ phosphorus level (>2.5 mg/dl) 12.3% 30.3% 6.5% 7.1%
‘Moderate’ hypophosphataemia (1.6–2.5 mg/dl) 8.0% 20.1% 3.8% 5.3%
‘Severe’ hypophosphataemia (1.1–1.5 mg/dl) 8.5% 19.5% 2.8% 3.8%
‘Profound’ Hypophosphataemia (<1.1 mg/dl) 3.4% 16.7% 0 3.4%
P = 0.008 P = 0.037 P = 0.010 P = 0.166
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edged that the development of some degree of postoperative
hypophosphataemia, even extreme hypophosphataemia, is a
normal, transient physiological sequela of hepatectomy; this
appropriate response is observed to some extent in nearly all
patients and corresponds to the increased metabolic demands of
the regenerating liver remnant. In fact, failure to develop
hypophosphataemia after a major hepatic resection may reflect a
lack of or inadequate liver regeneration, indicating patients at a
greater risk of PHI and complications. Based on the observation
of hypophosphataemia as a common and appropriate post-
operative consequence of a liver resection, it was hypothesized
that absence of or delayed development of hypophosphataemia
after a major resection may be associated with an increased risk
of PHI, major morbidity and mortality. Failure to develop
hypophosphataemia was defined as POD2 serum phosphorus
>2.4 mg/dl, as this represented the lower limit of the normal
institutional reference range. The timing of hypophosphataemia
after a hepatectomy was also examined. Delayed development of
appropriate hypophosphataemia was defined and independently
analysed as a serum phosphorus nadir occurring after POD3, as
previous studies have suggested that serum phosphorus
decreases dramatically over the first 72 h post-hepatectomy
before slowly returning to normal, preoperative levels. Indeed,
>80% of patients in the current cohort reached their serum
phosphorus nadir during POD 1–3 as expected.
Liver regeneration begins nearly immediately after a hepatec-
tomy, and DNA synthesis and hepatocyte proliferation within the
liver remnant are largely complete within 72 h.15,22,23 The increased
Table 3a Multivariate analysis of risk factors for post-operative hepatic insufficiency (PHI) and major complications after major hepatectomy
Variable PHI Major complications
HR 95% CI P-value HR 95% CI P-value
Male gender 1.15 0.63–2.11 0.637 1.21 0.79–1.86 0.366
ASA class 1.93 1.05–3.54 0.040 1.66 1.07–2.55 0.024
Pre-op albumin 0.65 0.38–1.08 0.103 0.61 0.40–0.93 0.019
Pre-op INR 3.88 0.90–16.68 0.068 2.50 0.47–12.50 0.290
Pre-op total bilirubin 1.24 1.06–1.45 0.006 1.02 0.87–1.11 0.755
Portal vein embolization 2.12 0.75–5.93 0.159 1.19 0.49–2.87 0.712
Bile duct resection 1.26 0.63–2.54 0.524 1.22 0.73–2.03 0.461
EBL 1.00 1.00–1.001 0.141 1.01 1.00–1.02 0.198
Intra-op transfusion 1.09 0.52–2.31 0.818 1.20 0.68–2.13 0.533
Cancer diagnosis 1.43 0.67–3.07 0.356 1.96 1.13–3.39 0.022
Cirrhosis 1.76 0.56–5.55 0.363 2.63 1.01–6.82 0.047
POD2 phosphorus > 2.4 1.78 1.02–3.17 0.048 1.57 1.02–2.47 0.049
Statistically significant variables (P < 0.05) indicated in bold. HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; EBL,
estimated blood loss; POD, post-operative-day 2.
Table 3b Multivariate analysis of risk factors for 30- and 90-day mortality after a major hepatectomy
Variable 30-day mortality 90-day mortality
HR 95% CI P-value HR 95% CI P-value
Male gender 2.05 0.87–4.81 0.097 1.21 0.59–2.49 0.596
ASA class 4.25 1.61–11.24 0.014 2.60 1.09–6.24 0.031
Pre-op albumin 0.68 0.31–1.50 0.330 0.53 0.27–1.04 0.069
Pre-op INR 1.75 0.03–10.61 0.712 1.02 0.11–9.13 0.983
Pre-op total bilirubin 1.02 0.83–1.22 0.896 1.03 0.80–1.19 0.778
Portal vein embolization 1.04 0.15–3.94 0.873 1.07 0.27–4.24 0.920
Bile duct resection 1.42 0.52–3.86 0.394 1.62 0.71–3.70 0.245
EBL 1.00 1.00–1.001 0.302 1.00 1.00–1.001 0.182
Intra-op transfusion 2.14 0.76–6.07 0.145 1.95 0.81–4.72 0.144
Cancer diagnosis 9.16 1.50–56.01 0.018 9.47 2.03–44.86 0.004
Cirrhosis 10.46 2.88–37.99 <0.001 8.68 2.71–27.79 <0.001
POD2 phosphorus > 2.4 2.70 1.08–6.76 0.031 2.51 1.03–6.15 0.044
Statistically significant variables (P < 0.05) indicated in bold. ASA, American Society of Anesthesiology; CI, confidence interval; EBL, estimated blood
loss; HR, hazard ratio; INR, international normalized ratio; PHI, post-operative hepatic insufficiency; POD2, post-operative day 2.
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rates of compensatory DNA replication and protein synthesis
within the liver remnant after a hepatectomy are accompanied by
dramatic increases in energy requirements, as evidenced by
enhanced adenosine triphosphate (ATP) consumption and
increased incorporation of radiolabelled phosphate by the
liver.12,13,17 Changes in hepatocyte energy consumption and phos-
phorus metabolism are observed in other acute stress phases such
as non-hepatic surgical intervention, but the magnitude of these
changes is most profound after a hepatectomy.17 The liver remnant
must support one or more rounds of hepatocyte mitosis while
maintaining hepatic synthetic and excretory functions with a frac-
tion of the original liver volume.14,15,17 This leads to dramatically
increased ATP consumption over the first 72 h, followed by
gradual restoration of the liver’s energy balance over the next days
to weeks.13,16–18
Several groups have suggested that increased hepatic uptake of
phosphorus by the regenerating liver remnant post-hepatectomy
cannot fully explain the magnitude of hypophosphataemia typi-
cally observed, and have demonstrated that increased urinary
excretion of phosphorus plays a significant role in this post-
operative phenomenon.24–28 This transient hyperphosphaturia
may be mediated by acute phase reactants or circulatory factors
released by the injured, regenerating liver or by disruption of
normal hepatorenal feedback mechanisms; these mechanisms are
still under investigation.25,27,28 The present study did not focus on
the molecular mechanisms underlying this phenomenon, but on
Table 3c Multivariate analysis of risk factors for post-operative hepatic insufficiency (PHI) and major complications after a major
hepatectomy
Variable PHI Major complications
HR 95% CI P-value HR 95% CI P-value
Gender 1.22 0.67–2.21 0.515 1.13 0.69–1.85 0.174
ASA class 1.92 1.05–3.52 0.039 1.77 1.04–3.02 0.037
Pre-op albumin 0.92 0.53–1.61 0.784 0.54 0.33–0.88 0.014
Pre-op INR 2.39 0.52–10.89 0.260 1.04 0.18–5.88 0.955
Pre-op total bilirubin 1.22 1.06–1.40 0.008 1.01 0.89–1.14 0.890
Portal vein embolization 2.47 0.91–6.73 0.083 1.73 0.65–4.62 0.266
Bile duct resection 1.36 0.69–2.67 0.377 1.20 0.64–2.25 0.581
EBL 1.00 1.00–1.001 0.142 1.00 1.00–1.001 0.479
Intra-op transfusion 1.23 0.59–2.60 0.578 1.23 0.66–2.31 0.506
Cancer diagnosis 1.36 0.64–2.89 0.421 1.23 0.67–2.27 0.514
Cirrhosis 1.67 0.56–5.03 0.362 1.94 0.80–4.72 0.148
Phos nadir after POD3 1.86 1.02–3.39 0.044 1.90 1.09–3.31 0.022
Statistically significant variables (P < 0.05) indicated in bold. HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; INR,
international normalized ratio; EBL, estimated blood loss; POD3, post-operative day 3.
Table 3d Multivariate analysis of risk factors for 30- and 90-day mortality after a major hepatectomy
Variable 30-day mortality 90-day mortality
HR 95% CI P-value HR 95% CI P-value
Gender 1.88 0.78–4.52 0.158 1.08 0.52–2.24 0.849
ASA class 3.60 1.45–8.96 0.014 2.13 0.94–4.81 0.072
Pre-op albumin 0.94 0.45–1.95 0.861 0.66 0.33–1.30 0.233
Pre-op INR 1.21 0.11–6.64 0.379 1.56 0.06–7.28 0.720
Pre-op total bilirubin 1.05 0.89–1.23 0.590 1.05 0.75–1.19 0.628
Portal vein embolization 1.06 0.21–5.38 0.936 1.30 0.34–4.93 0.704
Bile duct resection 1.90 0.77–4.69 0.163 1.56 0.69–3.57 0.285
EBL 1.00 1.00–1.01 0.131 1.00 1.00–1.01 0.421
Intra-op transfusion 2.79 1.01–7.70 0.047 3.32 1.40–7.86 0.012
Cancer diagnosis 6.43 1.14–36.34 0.049 5.36 1.43–20.12 0.008
Cirrhosis 7.56 2.34–24.45 0.001 6.84 2.42–19.35 <0.001
Phos nadir after POD3 2.39 1.09–5.72 0.045 2.11 0.99–4.49 0.054
Statistically significant variables (P < 0.05) indicated in bold. ASA, American Society of Anesthesiology; CI, confidence interval; EBL, estimated blood
loss; HR, hazard ratio; INR, international normalized ratio; POD3, postoperative day 3.
HPB 889
HPB 2014, 16, 884–891 © 2014 International Hepato-Pancreato-Biliary Association
the implications of failure to develop hypophosphataemia. The
regulation of serum phosphorus after a hepatectomy is probably
complex and multifactorial; the hypothesis regarding the absence
of physiological hypophosphataemia and the implications of per-
sistently elevated serum phosphorus as a marker of inadequate
liver regeneration is independent of the exact mechanisms gov-
erning serum phosphorus levels. Regardless of renal involvement
in the regulatory process, failure to develop hypophosphataemia
after a major hepatectomy appears to suggest inadequate liver
regeneration.
Contrary to several previous studies, a direct correlation
between severe hypophosphataemia and an increased risk of post-
operative complications was not observed.2,3,5 In fact, using the
categories of serum phosphorus levels as defined by George and
Shiu,2 patients with ‘normal’ phosphorus levels (>2.5 mg/dl) on
POD2 demonstrated the greatest risk of PHI, major complications
and early mortality, whereas those patients with ‘profound’
hypophosphataemia (<1.1 mg/dl) had the lowest risk of each of
these respective endpoints. Rather than a harbinger of post-
operative complications, profound hypophosphataemia may
simply represent a more extensive hepatic resection and a greater
synthetic and metabolic burden on the regenerating liver remnant.
These findings support the hypothesis that hypophosphataemia
after a major hepatectomy reflects appropriate liver regeneration
and that failure to develop hypophosphataemia or delayed
development of hypophosphataemia can identify patients
at increased risk of PHI, major complications and early
mortality.
Given the retrospective nature of this study, the relationships
of increased risk of PHI, complications and early mortality with
absent or delayed hypophosphataemia demonstrated in these
analyses are only associative in nature; no definitive conclusions
regarding causality can be drawn. An additional limitation of
this study was the lack of standardization of phosphorus reple-
tion. Previous retrospective studies have also struggled with this
limitation. While 69% of patients received some degree of phos-
phorus repletion over the first 72 h post-operatively, the range of
repletion quantities was large and did not follow a standard
protocol. Repletion was typically reactionary, in response to
hypophosphataemia, rather than empiric. Given the heterogene-
ity of repletion regimens, the role of phosphorus repletion was
analysed qualitatively, not quantitatively; phosphorus repletion
during the first 72 h was not associated with the risk of PHI,
major complications, or early mortality. Iatrogenic repletion of
patients with exogenous phosphorus after a hepatectomy may
slightly dampen the initial decline in serum levels and hasten the
return to normal preoperative levels, but neither the overall
propensity or timeline for developing post-operative
hypophosphataemia and the risk of associated complications
appear affected by repletion. Further investigation of
hypophosphataemia after a major hepatectomy in which phos-
phorus repletion is standardized post-operatively may help
confirm these findings.
Serum phosphorus levels persistently >2.4 mg/dl on POD2 and
a delayed nadir in phosphorus beyond POD3 are independently
associated with a significantly increased risk of post-operative
hepatic insufficiency, major complications and early mortality.
Failure to develop hypophosphataemia within 72 h after a major
hepatectomy may reflect insufficient liver remnant regeneration.
Early detection of these patients at risk for PHI, secondary compli-
cations and even post-operative mortality after a hepatectomy may
allow for earlier clinical intervention and potentially improved
outcomes. Serum phosphorus levels, specifically the absence of or
delayed development of physiologic hypophosphataemia after
major hepatic resection, may provide early prognostic data sug-
gesting inadequate liver regeneration and an increased risk of
post-operative hepatic insufficiency and accompanying morbidity
and mortality.
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